<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413617</url>
  </required_header>
  <id_info>
    <org_study_id>B7921023</org_study_id>
    <secondary_id>2019-002676-14</secondary_id>
    <nct_id>NCT04413617</nct_id>
  </id_info>
  <brief_title>TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE</brief_title>
  <official_title>A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual objectives of increased efficacy compared to currently available SoC RA drugs and
      maintaining a favourable benefit - risk relationship.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 16, 2020</start_date>
  <completion_date type="Anticipated">September 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Disease Activity Score (DAS)28-C Reactive protein (CRP)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP remission (&lt;2.6)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score (DAS)28-C Reactive protein (CRP)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 responder rates</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Tender/Painful and Swollen Joint Count</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Physician's Global Assessment (PhGA) of Arthritis</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, serious adverse events, and withdrawals due to adverse events.</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormality in clinical chemistry parameters</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormality in hematological parameters</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure measurement</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse rate measurement</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in temperature measurement</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of targeted medical adverse events</measure>
    <time_frame>Baseline through Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>PF-06650833 + tofacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06650833 + PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06650833</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tofacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06650833</intervention_name>
    <description>400 mg</description>
    <arm_group_label>PF-06650833</arm_group_label>
    <arm_group_label>PF-06650833 + PF-06651600</arm_group_label>
    <arm_group_label>PF-06650833 + tofacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>100 mg</description>
    <arm_group_label>PF-06650833 + PF-06651600</arm_group_label>
    <arm_group_label>PF-06651600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>11 mg</description>
    <arm_group_label>PF-06650833 + tofacitinib</arm_group_label>
    <arm_group_label>Tofacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants between the ages of 18 and 70 years.

          -  Participants who are willing and able to comply with all scheduled visits, treatment
             plan, laboratory tests, lifestyle considerations, and other study procedures.

          -  Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European
             League Against Rheumatism (EULAR) classification criteria for RA with a Total Score
             ≥6/10.

          -  The participant has active disease at both Screening and Randomization, as defined by
             both: ≥6 joints tender or painful on motion, AND ≥6 joints swollen; and fulfills 1 of
             the following 2 criteria: High sensitivity C reactive protein (hsCRP) &gt;7 mg/L at
             Screening (Visit 1) as performed by the central laboratory OR Erythrocyte
             sedimentation rate (ESR) (Westergren method) &gt;28 mm h.

        Exclusion Criteria:

          -  Other acute or chronic medical or psychiatric condition including recent (within the
             past year) or active suicidal ideation or behavior or laboratory abnormality that may
             increase the risk associated with study participation or IP administration or may
             interfere with the interpretation of study results and, in the judgment of the
             investigator, would make the participant inappropriate for entry into this study.

          -  Participants with a known immunodeficiency disorder or a first degree relative with a
             hereditary immunodeficiency.

          -  Participants with any active or latent infections.

          -  Participants with positive hepatitis B surface antigen (HBsAg).

          -  Participants with positive HCV Ab tests will be reflex tested for HCV ribonucleic acid
             (HCV RNA).

          -  Any history of either untreated or inadequately treated latent or active tuberculosis
             (TB) infection, current treatment for active or latent TB infection or evidence of
             currently active TB,

          -  History of a major organ transplant (eg, heart, lung, kidney and liver) or
             hematopoietic stem cell/marrow transplant.

          -  History of severe allergic or anaphylactoid reaction to kinase inhibitors, or
             corticosteroid preparations.

          -  Known history of diverticulitis or symptomatic diverticulosis, perineal abscess or
             fistulae.

          -  Participants with malignancy or history of malignancy (including lymphoma, leukemia,
             or lymphoproliferative disease).

          -  Pre-existing chronic autoimmune disease (eg, inflammatory bowel disease, systemic
             lupus erythematosus, moderate-severe atopic dermatitis, dermatomyositis) other than
             RA. Secondary Sjogren's Syndrome (due to RA) may be included.

          -  Participants with fibromyalgia will be excluded.

          -  Previous treatment with total lymphoid irradiation.

          -  Participants with an oral, tympanic, or temporal temperature of 38°C (100.4°F) or
             higher at baseline.

          -  Participants may not receive any live/attenuated vaccine from 30 days prior to
             randomization during the course of the study, or for 30 days after the last dose of
             study medication. Participants who have current routine household contact with
             children who have received varicella or oral polio vaccine within 2 months of first
             study dose are also excluded.

          -  History of any lymphoproliferative disorder.

          -  Have hearing loss with progression over the previous 5 years, sudden hearing loss, or
             middle or inner ear disease.

          -  History of any prior deep vein thrombosis (DVT) or pulmonary embolism [PE].

          -  Recent (within 6 months of screening) myocardial infarction, coronary
             revascularization, or percutaneous angioplasty with or without placement of a coronary
             artery stent; acute coronary syndrome; chronic uncompensated heart failure or New York
             Heart Association Functional Class III or IV; left ventricular assist devices;
             implanted defibrillators.

          -  Current severe chronic renal insufficiency or renal failure as defined by persistent
             (on repeated measurements) eGFR &lt;60 mL/min per 1.73 m2 based on the Chronic Kidney
             Disease Epidemiology Collaboration (CKD-EPI) calculation.

          -  Any known coagulopathy or hypercoagulant syndrome.

          -  Presence of any of the following laboratory abnormalities at screening or within the 3
             months prior to first study dose:

        Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥1.5 x the upper
        limit of normal (ULN); Participants with a history of Gilbert's syndrome may have a direct
        bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤
        ULN and other liver function assessments are normal; Absolute neutrophil count of &lt;1.5 x
        109/L (&lt;1500/mm3). Participants with cyclic (benign ethnic) neutropenia will be excluded;
        Absolute lymphocyte count of &lt;0.5 x 109/L (&lt;500/mm3); Absolute white blood cell (WBC) count
        of &lt;3.0 x 109/L (&lt;3000/mm3); Hemoglobin &lt;9.0 g/dL (90 g/L); Platelet count ≤100 x 109/L
        (100,000 cells/mm3) or ≥1000 x 109/L (1,000,000 cells/mm3); Thrombocytopenia, as defined by
        a platelet count &lt;100 x 109/L (&lt;100,000/mm3) at screening visit or within the 3 months
        prior to first study dose. [Screening laboratory tests with abnormal results may be
        repeated once to confirm abnormal results. If results return to normal protocol acceptable
        limits within the 4-week screening period, the participant may enter the study].

        - Grade 3 or greater laboratory abnormality based on the Common Terminology Criteria for
        Adverse Events (CTCAE) version 5.0 toxicity scale, except for the following that are
        allowed: Grade 3 prothrombin time (PT) secondary to warfarin treatment; Grade 3 partial
        thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or
        anti-coagulant therapy.

          -  Participants previously treated with a biologic DMARD (except for up to 25% of
             participants who may have been treated with 1, and only 1 prior TNF inhibitor) or any
             other recent DMARD treatment (eg, a JAK inhibitor), or participants currently treated
             with any other prohibited medications will be excluded.

          -  Prior use of tofacitinib or other JAK inhibitor in the context of a clinical trial is
             excluded. Concomitant use of tofacitinib (other than as prescribed by the
             randomization scheme) or other JAK inhibitor is prohibited.

          -  Participants who have previously been treated with other, non-TNFa inhibiting biologic
             DMARDs [including, abatacept (Orencia®), tocilizumab (Actemra®), Sarilumab (Kevzara®),
             anakinra (Kineret®), rituximab (Rituxan®) or other selective B lymphocyte depleting
             agents, or other lymphocyte depleting agents/therapies (such as alemtuzab [CamPath®],
             natalizumab (Tysabri®), alkylating agents [eg, cyclophosphamide or chlorambucil],
             total lymphoid irradiation) are excluded from participation in the study.

          -  Previous administration with an investigational drug within 30 days (or as determined
             by the local requirement) or 5 half-lives preceding the first dose of IP used in this
             study (whichever is longer).

          -  Any 12-lead electrocardiogram (ECG) performed prior to randomization that demonstrates
             clinically relevant abnormalities that may affect participant safety or interpretation
             of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Pharma Kft.</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasutegeszsegugyi Nonprofit Kozhasznu Tarsasag</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mammut Egeszsegkozpont, Ful-orr- gegeszet</name>
      <address>
        <city>Budapest</city>
        <zip>1024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affidea Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1054</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affidea Magyarorszag Kft. Vaci Greens Egeszsegkozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1138</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agria-Study Kft.</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Korhaz, Ful-orr-gegeszeti osztaly</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Korhaz</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanitas Diagnosztikai es Rehabilitacios Kozpont</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Gaias - Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7921023</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

